Fatigue News and Research

RSS

New patient-centered mobile app launched for breast cancer patients

Apple and Sage Bionetworks, together with UCLA cancer research pioneer and collaborator Dr. Patricia Ganz, today announced the launch of Share the Journey: Mind, Body and Wellness after Breast Cancer, a patient-centered mobile app that empowers women to be partners in the research process by tracking their symptoms and successes.

10 Mar 2015

Researchers use stem cells from sickle cell disease patients to grow mature red blood cells

Researchers at Johns Hopkins have successfully corrected a genetic error in stem cells from patients with sickle cell disease, and then used those cells to grow mature red blood cells, they report. The study represents an important step toward more effectively treating certain patients with sickle cell disease who need frequent blood transfusions and currently have few options.

10 Mar 2015

Depression symptoms under-recognized in African-American cancer patients

Case Western Reserve University nurse scientist Amy Zhang, who has long examined quality-of-life issues in cancer patients, wondered whether depression in African-American cancer patients has been under-recognized for treatment.

10 Mar 2015

Using IT devices may put your muscles and joints under particular strain

Spending hours on a computer or sending lots of text messages on a mobile phone can result in a stiff neck and sometimes even a strained thumb. Computer scientists in Saarbrücken have developed a procedure that simulates in a lifelike manner which muscles and joints are put under particular strain when using IT devices. It also demonstrates the speed and accuracy with which a user can operate a device.

10 Mar 2015

Pacritinib for myelofibrosis meets primary endpoint in Phase 3 PERSIST-1 trial

CTI BioPharma Corp. and Baxter International Inc. today announced positive top-line results for the primary endpoint from PERSIST-1, the randomized, controlled Phase 3 registration clinical trial examining pacritinib, a next generation oral JAK2/FLT3 multikinase inhibitor, for the treatment of patients with primary or secondary myelofibrosis.

From Baxter International Inc. 9 Mar 2015

DePaul University experts available to discuss different health care topics

With the fifth anniversary of the presidential signing of the U.S. Affordable Care Act March 23, faculty experts from DePaul University are available to discuss a range of health care topics including the analysis of health care data, community health, patient experience, communication among health care professionals, interprofessional health care education and the role of nurses and physician assistants.

6 Mar 2015

Study shows heart valve repair can benefit patients with mitral regurgitation

Patients with severe mitral regurgitation (MR) often suffer from psycho-emotional symptoms, such as depression and anxiety, but after undergoing mitral valve repair surgery patients experience a marked improvement in emotional and physical wellbeing, according to an article in the March 2015 issue of The Annals of Thoracic Surgery.

2 Mar 2015

Routledge Journals' new special issue focuses on CFS, ME/CFS and ME research

Routledge Journals is pleased to announce a new Special Issue from the Journal of Prevention & Intervention in the Community exploring topics and constructs that could help clarify uncertainties surrounding Chronic Fatigue Syndrome (CFS), Myalgic Encephalomyelitis/Chronic Fatigue Syndrome (ME/CFS), or Myalgic Encephalomyelitis (ME) research.

28 Feb 2015

Indiana University study reveals connection between mussels and muscles

An Indiana University study has revealed that there may be a greater connection between mussels and muscles than previously thought.

25 Feb 2015

Two widely used targeted therapy drugs not effective in preventing return of kidney cancer

Two widely used targeted therapy drugs— approved by the FDA for use in metastatic kidney cancer —are no more effective than a placebo in preventing return of the disease to increase life spans of patients suffering from advanced kidney cancer after surgery, according to new results to be presented by a researcher at the University of Pennsylvania's Abramson Cancer Center during the 2015 Genitourinary Cancers Symposium.

24 Feb 2015

Smartphones, tablets can do damage to overall health in unexpected ways

Despite the many benefits of having information at your fingertips, smartphones and tablets can do damage to your body and overall health in unexpected ways.

21 Feb 2015

Novartis’ heart failure medicine LCZ696 granted FDA priority review

LCZ696, a twice-a-day medicine being investigated for heart failure, acts to enhance the protective neurohormonal systems of the heart (NP system) while simultaneously suppressing the harmful effects of the overactive renin-angiotensin-aldosterone system (RAAS).

16 Feb 2015

Hospira announces launch of first biosimilar monoclonal antibody in Europe

Hospira, Inc., a world leader in the development of biosimilar therapies, today announced the launch of the first biosimilar monoclonal antibody (mAb), Inflectra (infliximab), in major European markets.

16 Feb 2015

Novartis receives priority review status from FDA for heart failure medicine LCZ696

Novartis announced today that the US Food and Drug Administration has granted priority review for LCZ696, an investigational medicine for the treatment of heart failure with reduced ejection fraction (HFrEF). The designation is intended to accelerate the review of therapies that offer a significant improvement in the safety or effectiveness of the treatment, prevention or diagnosis of a serious condition.

16 Feb 2015

$Eisai announces FDA approval of LENVIMA (lenvatinib) for treatment of RAI-refractory DTC$

Eisai announces FDA approval of LENVIMA (lenvatinib) for treatment of RAI-refractory DTC

Eisai Inc. announced today that the U.S. Food and Drug Administration approved the company's receptor tyrosine kinase inhibitor LENVIMA (lenvatinib) for the treatment of locally recurrent or metastatic, progressive, radioactive iodine-refractory differentiated thyroid cancer (RAI-R DTC).

13 Feb 2015

Camp Twinkletoes improves lives of children suffering from juvenile arthritis

Throughout NSW, there are more than 6,000 children suffering from the extreme pain and fatigue of juvenile arthritis. Usually thought of as an ‘older persons’ disease, arthritis in children is a very real condition, and in extreme cases can even result in death.

13 Feb 2015

Lenvatinib trial offers hope for thyroid cancer patients

A new targeted therapy called lenvatinib has been shown to improve progression-free survival among patients with advanced thyroid cancer that is not responsive to iodine-131.

13 Feb 2015

Doctor's Best adds three new sports nutrition powders to its science-based supplement portfolio

Doctor's Best has introduced three new sports nutrition powders – Creatine, Branched Chain Amino Acids (BCAA) and L-Arginine - into its science-based supplement portfolio.

13 Feb 2015

$Lenvatinib therapy improves survival in patients with advanced radioiodine-refractory thyroid cancer$

Lenvatinib therapy improves survival in patients with advanced radioiodine-refractory thyroid cancer

In a pivotal Phase III study led by researchers at The University of Texas MD Anderson Cancer Center, the oral anti-angiogenic therapy lenvatinib has shown dramatic improvement in progression-free survival in patients with advanced radioiodine-refractory thyroid cancer.

12 Feb 2015

New online tool helps facilitate discussion between health professionals and patients presenting with fatigue

In Australia, people often seek medical advice because of fatigue. However it is often not associated with underlying disease, particularly in young to middle aged adults, and may remain unexplained.

11 Feb 2015

Fatigue News and Research

New patient-centered mobile app launched for breast cancer patients

Researchers use stem cells from sickle cell disease patients to grow mature red blood cells

Depression symptoms under-recognized in African-American cancer patients

Using IT devices may put your muscles and joints under particular strain

Pacritinib for myelofibrosis meets primary endpoint in Phase 3 PERSIST-1 trial

DePaul University experts available to discuss different health care topics

Study shows heart valve repair can benefit patients with mitral regurgitation

Routledge Journals' new special issue focuses on CFS, ME/CFS and ME research

Indiana University study reveals connection between mussels and muscles

Two widely used targeted therapy drugs not effective in preventing return of kidney cancer

Smartphones, tablets can do damage to overall health in unexpected ways

Novartis’ heart failure medicine LCZ696 granted FDA priority review

Hospira announces launch of first biosimilar monoclonal antibody in Europe

Novartis receives priority review status from FDA for heart failure medicine LCZ696

Eisai announces FDA approval of LENVIMA (lenvatinib) for treatment of RAI-refractory DTC

Camp Twinkletoes improves lives of children suffering from juvenile arthritis

Lenvatinib trial offers hope for thyroid cancer patients

Doctor's Best adds three new sports nutrition powders to its science-based supplement portfolio

Lenvatinib therapy improves survival in patients with advanced radioiodine-refractory thyroid cancer

New online tool helps facilitate discussion between health professionals and patients presenting with fatigue

Advancing Intracellular Delivery with LumiPore®

How ELRIG Is Helping Mid-Career Scientists Navigate Leadership, Career Change and Redundancy

The role of UV-Vis in biopharma QC

Latest News